Black Diamond Therapeutics (BDTX) Change in Acquisitions & Divestments (2020 - 2026)

Black Diamond Therapeutics (BDTX) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $19.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 39.06% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.6 million (down 20.0% YoY) and the FY2025 annual result came in at $119.1 million, down 14.78% from the prior year.
• Change in Acquisitions & Divestments eased to $19.5 million in Q1 2026, from $33.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $40.5 million in Q2 2024 to a low of $8.2 million in Q3 2023.
• A 5-year average of $27.7 million and a median of $30.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments tumbled 72.91% — and 2024, when it soared 263.64%.
• Tracing BDTX's Change in Acquisitions & Divestments over 5 years: stood at $26.0 million in 2022, then increased by 7.83% to $28.0 million in 2023, then grew by 9.68% to $30.8 million in 2024, then advanced by 7.35% to $33.0 million in 2025, then slumped by 40.93% to $19.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $19.5 million (Q1 2026), $33.0 million (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.